Related Experiment Video

Updated: Mar 21, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.0K

Reporting results for deep molecular responses in chronic myeloid leukemia

A A Morley1

  • 1Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, South Australia, Australia.

Leukemia
|May 18, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 21, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K

Articles linked to this work by shared authors, journal, and citation graph.

The PKZ1 recombination mutation assay: a sensitive assay for low dose studies.

Dose-response : a publication of International Hormesis Society·2008

Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.

Tissue antigens·2002

Lack of an effect of vitamin E on lifespan of mice.

Biogerontology·2001

Effect of exposure to 900 MHz radiofrequency radiation on intrachromosomal recombination in pKZ1 mice.

Radiation research·2001

Purging of myeloma cells using all-trans retinoic acid in a mouse model.

Experimental hematology·2001

Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia.

Leukemia·2001

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Leukemia·2026

Cheminformatic identification of small molecules targeting acute myeloid leukemia.

Leukemia·2026

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Leukemia·2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

Leukemia·2026

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

Leukemia·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us